Maxcyte Stock Analysis
| MXCT Stock | USD 1.55 0.01 0.64% |
MaxCyte holds a debt-to-equity ratio of 0.056. At this time, MaxCyte's Short and Long Term Debt Total is comparatively stable compared to the past year. Short Term Debt is likely to gain to about 781.2 K in 2026, whereas Short and Long Term Debt is likely to drop slightly above 680.7 K in 2026. MaxCyte's financial risk is the risk to MaxCyte stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
MaxCyte's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. MaxCyte's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps MaxCyte Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect MaxCyte's stakeholders.
For most companies, including MaxCyte, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for MaxCyte, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, MaxCyte's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
At this time, MaxCyte's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 21.1 M in 2026, whereas Total Current Liabilities is likely to drop slightly above 10.3 M in 2026. MaxCyte is undervalued with Real Value of 2.78 and Target Price of 6.68. The main objective of MaxCyte stock analysis is to determine its intrinsic value, which is an estimate of what MaxCyte is worth, separate from its market price. There are two main types of MaxCyte's stock analysis: fundamental analysis and technical analysis.
The MaxCyte stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. MaxCyte is usually not traded on Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday. MaxCyte Stock trading window is adjusted to America/New York timezone.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MaxCyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. MaxCyte Stock Analysis Notes
About 75.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.92. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MaxCyte recorded a loss per share of 0.43. The entity had not issued any dividends in recent years. MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. The company was incorporated in 1998 and is headquartered in Rockville, Maryland. Maxcyte operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 84 people. To find out more about MaxCyte contact Maher Masoud at 301 944 1700 or learn more at https://www.maxcyte.com.MaxCyte Quarterly Total Revenue |
|
MaxCyte Investment Alerts
| MaxCyte generated a negative expected return over the last 90 days | |
| MaxCyte may become a speculative penny stock | |
| MaxCyte has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 38.63 M. Net Loss for the year was (41.05 M) with profit before overhead, payroll, taxes, and interest of 27.53 M. | |
| MaxCyte currently holds about 240.89 M in cash with (27.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 75.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: MaxCyte Shares Struggle to Regain Footing Amid Restructuring - AD HOC NEWS |
MaxCyte Upcoming and Recent Events
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
MaxCyte Largest EPS Surprises
Earnings surprises can significantly impact MaxCyte's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-08 | 2023-09-30 | -0.1 | -0.11 | -0.01 | 10 | ||
2021-09-13 | 2021-06-30 | -0.06 | -0.05 | 0.01 | 16 | ||
2025-08-06 | 2025-06-30 | -0.1 | -0.12 | -0.02 | 20 |
MaxCyte Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2025-06-30 | 1.7 M | Chevy Chase Trust Holdings, Inc. | 2025-06-30 | 1.7 M | Silvercrest Asset Management Group Llc | 2025-06-30 | 1.1 M | Citadel Advisors Llc | 2025-06-30 | 1 M | Northern Trust Corp | 2025-06-30 | 785.8 K | Renaissance Technologies Corp | 2025-06-30 | 717.8 K | Royce & Associates, Lp | 2025-06-30 | 657.1 K | Goldman Sachs Group Inc | 2025-06-30 | 442.6 K | Rice Hall James & Associates, Llc | 2025-06-30 | 417.8 K | Blackrock Inc | 2025-06-30 | 10.2 M | Cadian Capital Management Lp | 2025-06-30 | 8.9 M |
MaxCyte Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 165.34 M.MaxCyte Profitablity
The company has Profit Margin (PM) of (1.33) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.62) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.62.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.26) | (0.25) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.23) | (0.22) |
Management Efficiency
MaxCyte has return on total asset (ROA) of (0.1367) % which means that it has lost $0.1367 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2319) %, meaning that it created substantial loss on money invested by shareholders. MaxCyte's management efficiency ratios could be used to measure how well MaxCyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.16 in 2026. Return On Capital Employed is likely to gain to -0.25 in 2026. At this time, MaxCyte's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 21.1 M in 2026, whereas Total Current Liabilities is likely to drop slightly above 10.3 M in 2026.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.77 | 1.86 | |
| Tangible Book Value Per Share | 1.77 | 1.86 | |
| Enterprise Value Over EBITDA | (8.27) | (8.68) | |
| Price Book Value Ratio | 1.90 | 2.00 | |
| Enterprise Value Multiple | (8.27) | (8.68) | |
| Price Fair Value | 1.90 | 2.00 | |
| Enterprise Value | 526.2 M | 696.4 M |
MaxCyte showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Technical Drivers
As of the 6th of January, MaxCyte secures the Risk Adjusted Performance of 0.0163, mean deviation of 3.4, and Downside Deviation of 4.7. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of MaxCyte, as well as the relationship between them.MaxCyte Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Simple Moving Average indicator is calculated by adding the closing price of MaxCyte for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out MaxCyte short-term fluctuations and highlight longer-term trends or cycles.
MaxCyte Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MaxCyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on MaxCyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MaxCyte insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
MaxCyte Outstanding Bonds
MaxCyte issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. MaxCyte uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most MaxCyte bonds can be classified according to their maturity, which is the date when MaxCyte has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
MaxCyte Predictive Daily Indicators
MaxCyte intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of MaxCyte stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
MaxCyte Forecast Models
MaxCyte's time-series forecasting models are one of many MaxCyte's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary MaxCyte's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.MaxCyte Bond Ratings
MaxCyte financial ratings play a critical role in determining how much MaxCyte have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for MaxCyte's borrowing costs.| Piotroski F Score | 5 | Healthy | View |
| Beneish M Score | (2.59) | Unlikely Manipulator | View |
MaxCyte Debt to Cash Allocation
MaxCyte currently holds 18.03 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. MaxCyte has a current ratio of 13.96, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about MaxCyte's use of debt, we should always consider it together with its cash and equity.MaxCyte Total Assets Over Time
MaxCyte Assets Financed by Debt
The debt-to-assets ratio shows the degree to which MaxCyte uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.MaxCyte Debt Ratio | 8.23 |
MaxCyte Corporate Bonds Issued
MaxCyte Short Long Term Debt Total
Short Long Term Debt Total |
|
About MaxCyte Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how MaxCyte prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling MaxCyte shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as MaxCyte. By using and applying MaxCyte Stock analysis, traders can create a robust methodology for identifying MaxCyte entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (1.22) | (1.16) | |
| Operating Profit Margin | (1.52) | (1.45) | |
| Net Loss | (1.22) | (1.16) | |
| Gross Profit Margin | 0.94 | 0.97 |
Current MaxCyte Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. MaxCyte analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. MaxCyte analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 6.68 | Strong Buy | 6 | Odds |
Most MaxCyte analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand MaxCyte stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of MaxCyte, talking to its executives and customers, or listening to MaxCyte conference calls.
MaxCyte Stock Analysis Indicators
MaxCyte stock analysis indicators help investors evaluate how MaxCyte stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading MaxCyte shares will generate the highest return on investment. By understating and applying MaxCyte stock analysis, traders can identify MaxCyte position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 46.5 M | |
| Common Stock Shares Outstanding | 104.8 M | |
| Total Stockholder Equity | 206.3 M | |
| Total Cashflows From Investing Activities | 6.9 M | |
| Property Plant And Equipment Net | 30.5 M | |
| Cash And Short Term Investments | 154.5 M | |
| Cash | 27.9 M | |
| Accounts Payable | 1.4 M | |
| Net Debt | -9.8 M | |
| 50 Day M A | 1.5776 | |
| Total Current Liabilities | 15.8 M | |
| Other Operating Expenses | 89.8 M | |
| Non Current Assets Total | 67.8 M | |
| Non Currrent Assets Other | 1.5 M | |
| Stock Based Compensation | 13.1 M |
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.